Arielle L. Heeke , Wei Sha , Rebecca Feldman , Julie Fisher , Lejla Hadzikadic-Gusic , James T. Symanowski , Richard L. White Jr , Antoinette R. Tan
{"title":"The Genomic Landscape of Breast Cancer in Young and Older Women","authors":"Arielle L. Heeke , Wei Sha , Rebecca Feldman , Julie Fisher , Lejla Hadzikadic-Gusic , James T. Symanowski , Richard L. White Jr , Antoinette R. Tan","doi":"10.1016/j.clbc.2024.07.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Young women with breast cancer (YWBC; ≤40 years) often have a poorer prognosis than older women with breast cancer (OWBC; ≥65 years). We explored molecular features of tumors from YWBC and OWBC to identify a biologic connection for these patterns.</p></div><div><h3>Materials and Methods</h3><p>We retrospectively analyzed the molecular profiles of 1879 breast tumors. Testing included immunohistochemistry (IHC), <em>in situ</em> hybridization (ISH), and next-generation sequencing. Statistical analyses included Pearson's chi<sup>2</sup> test for comparisons, with significance defined as FDR (false discovery rate)-<em>P</em> < .05.</p></div><div><h3>Results</h3><p><em>TP53</em> and <em>BRCA1</em> somatic mutations were more common in YWBC tumors than in OWBC tumors (53%, 42%; <em>P</em> = .0001, FDR<em>-P</em> = .0025 and 7%, 2%; <em>P</em> = .0001, FDR<em>-P</em> = .0025; respectively). Conversely, OWBC tumors had higher androgen receptor expression (55%, 45%; <em>P</em> = .0002, FDR<em>-P</em> = .0025) higher PD-L1 expression detected by IHC (8%, 5%; <em>P</em> = .0476, FDR<em>-P</em> = .2754), and more frequent <em>PIK3CA</em> mutations (33%, 17%; <em>P</em> = < .0001, FDR<em>-P</em> = < .0001). Among HR+/HER2- samples, YWBC had more gene amplifications in FGF3 (27%, 10%; <em>P</em> = .0353, FDR<em>-P</em> = .2462), FGF4 (27%, 9%; <em>P</em> = .0218, FDR<em>-P</em> = .1668), FGF19 (30%, 12%; <em>P</em> = .034, FDR<em>-P</em> = .2462) and CCND1 (37%, 18%; <em>P</em> = .0344, FDR<em>-P</em> = .2462) than OWBC.</p></div><div><h3>Conclusions</h3><p>Our data suggest distinct molecular aberrations exist between YWBC and OWBC. Exploiting these molecular changes could refine our treatment strategies in YWBC and OWBC.</p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"24 7","pages":"Pages 630-638.e3"},"PeriodicalIF":2.9000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1526820924002064","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Young women with breast cancer (YWBC; ≤40 years) often have a poorer prognosis than older women with breast cancer (OWBC; ≥65 years). We explored molecular features of tumors from YWBC and OWBC to identify a biologic connection for these patterns.
Materials and Methods
We retrospectively analyzed the molecular profiles of 1879 breast tumors. Testing included immunohistochemistry (IHC), in situ hybridization (ISH), and next-generation sequencing. Statistical analyses included Pearson's chi2 test for comparisons, with significance defined as FDR (false discovery rate)-P < .05.
Results
TP53 and BRCA1 somatic mutations were more common in YWBC tumors than in OWBC tumors (53%, 42%; P = .0001, FDR-P = .0025 and 7%, 2%; P = .0001, FDR-P = .0025; respectively). Conversely, OWBC tumors had higher androgen receptor expression (55%, 45%; P = .0002, FDR-P = .0025) higher PD-L1 expression detected by IHC (8%, 5%; P = .0476, FDR-P = .2754), and more frequent PIK3CA mutations (33%, 17%; P = < .0001, FDR-P = < .0001). Among HR+/HER2- samples, YWBC had more gene amplifications in FGF3 (27%, 10%; P = .0353, FDR-P = .2462), FGF4 (27%, 9%; P = .0218, FDR-P = .1668), FGF19 (30%, 12%; P = .034, FDR-P = .2462) and CCND1 (37%, 18%; P = .0344, FDR-P = .2462) than OWBC.
Conclusions
Our data suggest distinct molecular aberrations exist between YWBC and OWBC. Exploiting these molecular changes could refine our treatment strategies in YWBC and OWBC.
期刊介绍:
Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.